Home
Archives
Jerusalem Center Homepage
View the current issue
Jerusalem Center Videos
Additional Resources
Top Commentators:
- Elliott Abrams
- Fouad Ajami
- Shlomo Avineri
- Benny Avni
- Alan Dershowitz
- Jackson Diehl
- Dore Gold
- Daniel Gordis
- Tom Gross
- Jonathan Halevy
- David Ignatius
- Pinchas Inbari
- Jeff Jacoby
- Efraim Karsh
- Mordechai Kedar
- Charles Krauthammer
- Emily Landau
- David Makovsky
- Aaron David Miller
- Benny Morris
- Jacques Neriah
- Marty Peretz
- Melanie Phillips
- Daniel Pipes
- Harold Rhode
- Gary Rosenblatt
- Jennifer Rubin
- David Schenkar
- Shimon Shapira
- Jonathan Spyer
- Gerald Steinberg
- Bret Stephens
- Amir Taheri
- Josh Teitelbaum
- Khaled Abu Toameh
- Jonathan Tobin
- Michael Totten
- Michael Young
- Mort Zuckerman
Think Tanks:
- American Enterprise Institute
- Brookings Institution
- Center for Security Policy
- Council on Foreign Relations
- Heritage Foundation
- Hudson Institute
- Institute for Contemporary Affairs
- Institute for Counter-Terrorism
- Institute for Global Jewish Affairs
- Institute for National Security Studies
- Institute for Science and Intl. Security
- Intelligence and Terrorism Information Center
- Investigative Project
- Jerusalem Center for Public Affairs
- RAND Corporation
- Saban Center for Middle East Policy
- Shalem Center
- Washington Institute for Near East Policy
Media:
- CAMERA
- Daily Alert
- Jewish Political Studies Review
- MEMRI
- NGO Monitor
- Palestinian Media Watch
- The Israel Project
- YouTube
Government:
Back
(Times of Israel) Shoshanna Solomon - "Roughly almost half of (our) healthcare revenue is based on innovation stemming from Israel," Kai Beckmann, CEO of Performance Materials at Germany's Merck pharmaceutical and chemicals firm, said in an interview on Tuesday. The Rebif drug marketed by Merck to help decrease the frequency of relapse symptoms of multiple sclerosis had sales of 1.7 billion euros in 2016, while the Erbitux drug for patients with cancer of the head and neck, also based on Israeli technology, had global sales of 1 billion euros. Beckmann was in Israel to inaugurate a new technology innovation laboratory at its subsidiary, Qlight Nanotech, in Jerusalem.2018-02-09 00:00:00Full Article
Israeli Innovation Makes Up Half of Merck Healthcare Revenue
(Times of Israel) Shoshanna Solomon - "Roughly almost half of (our) healthcare revenue is based on innovation stemming from Israel," Kai Beckmann, CEO of Performance Materials at Germany's Merck pharmaceutical and chemicals firm, said in an interview on Tuesday. The Rebif drug marketed by Merck to help decrease the frequency of relapse symptoms of multiple sclerosis had sales of 1.7 billion euros in 2016, while the Erbitux drug for patients with cancer of the head and neck, also based on Israeli technology, had global sales of 1 billion euros. Beckmann was in Israel to inaugurate a new technology innovation laboratory at its subsidiary, Qlight Nanotech, in Jerusalem.2018-02-09 00:00:00Full Article
Search Daily Alert
|
Search:
|